Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

OWP Pharmaceuticals Announces Patent Application for Treatment of Attention Deficit Hyperactivity Disorder

americanpharmaceuticalreviewApril 23, 2021

Tag: OWP , atomoxetine hydrochloride , ADHD

PharmaSources Customer Service